Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Infinity Pharmaceuticals, Inc. (INFI) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Infinity Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1113148.
Total stock buying since 2014: $18,039,399.
Total stock sales since 2014: $27,665,340.
Total stock option exercises since 2014: $356,586.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 0 | $0 | 410,196 | $28,713 | 768,133 | $0 |
| 2022 | 0 | $0 | 14,994 | $9,926 | 50,000 | $0 |
| 2021 | 0 | $0 | 5,848,520 | $24,207,024 | 5,000 | $4,600 |
| 2018 | 8,102,849 | $13,034,270 | 38,626 | $85,370 | 0 | $0 |
| 2017 | 2,104,425 | $2,918,942 | 6,250 | $21,750 | 0 | $0 |
| 2016 | 1,598,716 | $2,086,187 | 75,000 | $96,299 | 0 | $0 |
| 2015 | 0 | $0 | 94,737 | $1,385,554 | 4,737 | $9,663 |
| 2014 | 0 | $0 | 132,275 | $1,830,704 | 43,445 | $342,323 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-09 | 0 | $0 | 410,196 | $28,713 | 768,133 | $0 |
| 2022-08 | 0 | $0 | 14,994 | $9,926 | 50,000 | $0 |
| 2021-05 | 0 | $0 | 0 | $0 | 5,000 | $4,600 |
| 2021-01 | 0 | $0 | 5,848,520 | $24,207,024 | 0 | $0 |
| 2018-12 | 175,000 | $210,000 | 0 | $0 | 0 | $0 |
| 2018-11 | 2,475,758 | $3,349,820 | 0 | $0 | 0 | $0 |
| 2018-10 | 0 | $0 | 5,000 | $14,100 | 0 | $0 |
| 2018-08 | 0 | $0 | 14,313 | $28,683 | 0 | $0 |
| 2018-06 | 3,942,091 | $6,504,450 | 14,313 | $28,697 | 0 | $0 |
| 2018-04 | 1,510,000 | $2,970,000 | 0 | $0 | 0 | $0 |
| 2018-03 | 0 | $0 | 5,000 | $13,890 | 0 | $0 |
| 2017-12 | 500,000 | $905,000 | 0 | $0 | 0 | $0 |
| 2017-10 | 1,600,046 | $2,008,075 | 0 | $0 | 0 | $0 |
| 2017-03 | 0 | $0 | 6,250 | $21,750 | 0 | $0 |
| 2017-01 | 4,379 | $5,867 | 0 | $0 | 0 | $0 |
| 2016-12 | 1,598,716 | $2,086,187 | 75,000 | $96,299 | 0 | $0 |
| 2015-06 | 0 | $0 | 9,737 | $106,614 | 0 | $0 |
| 2015-05 | 0 | $0 | 20,000 | $249,900 | 0 | $0 |
| 2015-04 | 0 | $0 | 0 | $0 | 4,737 | $9,663 |
| 2015-03 | 0 | $0 | 45,000 | $732,500 | 0 | $0 |
| 2015-01 | 0 | $0 | 20,000 | $296,540 | 0 | $0 |
| 2014-12 | 0 | $0 | 4,737 | $77,293 | 4,737 | $9,663 |
| 2014-11 | 0 | $0 | 4,736 | $71,040 | 4,736 | $9,661 |
| 2014-10 | 0 | $0 | 0 | $0 | 24,500 | $303,677 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-09-12 | Perkins Adelene Q (Director) | Sale | 410,196 | .07 | 28,713 |
| 2023-09-09 | Perkins Adelene Q (Director) | Option Ex | 768,133 | .00 | 0 |
| 2022-08-02 | Peluso Stephane (Chief Scientific Officer) | Sale | 14,994 | .66 | 9,926 |
| 2022-08-02 | Peluso Stephane (Chief Scientific Officer) | Option Ex | 50,000 | .00 | 0 |
| 2021-05-14 | Selby Norman C | Option Ex | 5,000 | .92 | 4,600 |
| 2021-01-22 | Lampert Mark N | Sale | 5,848,520 | 4.14 | 24,207,024 |
| 2018-12-13 | Lampert Mark N | Buy | 175,000 | 1.20 | 210,000 |
| 2018-11-28 | Lampert Mark N | Buy | 100,000 | 1.30 | 130,000 |
| 2018-11-21 | Lampert Mark N | Buy | 4,700 | 1.35 | 6,345 |
| 2018-11-19 | Lampert Mark N | Buy | 1,465,126 | 1.36 | 1,992,571 |
| 2018-11-15 | Lampert Mark N | Buy | 91,474 | 1.35 | 123,489 |
| 2018-11-14 | Lampert Mark N | Buy | 210,250 | 1.34 | 281,735 |
| 2018-11-13 | Lampert Mark N | Buy | 604,208 | 1.35 | 815,680 |
| 2018-10-01 | Perkins Adelene Q (Chief Executive Officer) | Sale | 5,000 | 2.82 | 14,100 |
| 2018-08-16 | Kutok Jeffery (Chief Scientific Officer) | Sale | 6,133 | 2.00 | 12,266 |
| 2018-08-15 | Kutok Jeffery (Chief Scientific Officer) | Sale | 8,180 | 2.01 | 16,417 |
| 2018-06-22 | Kutok Jeffery (Chief Scientific Officer) | Sale | 14,313 | 2.00 | 28,697 |
| 2018-06-21 | Lampert Mark N | Buy | 425,531 | 1.65 | 702,126 |
| 2018-06-19 | Lampert Mark N | Buy | 3,516,560 | 1.65 | 5,802,324 |
| 2018-04-10 | Lampert Mark N | Buy | 1,010,000 | 2.00 | 2,020,000 |
| 2018-04-09 | Lampert Mark N | Buy | 500,000 | 1.90 | 950,000 |
| 2018-03-05 | Perkins Adelene Q (Chief Executive Officer) | Sale | 5,000 | 2.78 | 13,890 |
| 2017-12-06 | Bloch Lawrence E (President) | Buy | 500,000 | 1.81 | 905,000 |
| 2017-10-04 | Lampert Mark N | Buy | 653,449 | 1.28 | 839,028 |
| 2017-10-03 | Lampert Mark N | Buy | 946,597 | 1.24 | 1,169,047 |
| 2017-03-17 | Venuti Michael C (Director) | Sale | 6,250 | 3.48 | 21,750 |
| 2017-01-03 | Lampert Mark N | Buy | 4,379 | 1.34 | 5,867 |
| 2016-12-30 | Lampert Mark N | Buy | 3,553 | 1.34 | 4,761 |
| 2016-12-28 | Lampert Mark N | Buy | 738,848 | 1.34 | 987,100 |
| 2016-12-20 | Lampert Mark N | Buy | 22,001 | 1.35 | 29,811 |
| 2016-12-19 | Lampert Mark N | Buy | 198,264 | 1.36 | 269,242 |
| 2016-12-16 | Lampert Mark N | Buy | 434,656 | 1.28 | 556,359 |
| 2016-12-13 | Kango Sujay (Chief Commercial Officer) | Sale | 49,991 | 1.27 | 63,688 |
| 2016-12-12 | Kango Sujay (Chief Commercial Officer) | Sale | 25,009 | 1.30 | 32,611 |
| 2016-12-02 | Lampert Mark N | Buy | 52,500 | 1.19 | 62,475 |
| 2016-12-01 | Lampert Mark N | Buy | 148,894 | 1.19 | 176,439 |
| 2015-06-25 | Perkins Adelene Q (President & CEO) | Sale | 5,000 | 10.93 | 54,650 |
| 2015-06-15 | Palombella Vito J. (Chief Scientific Officer) | Sale | 4,737 | 10.97 | 51,964 |
| 2015-05-27 | Perkins Adelene Q (President & CEO) | Sale | 10,000 | 12.81 | 128,100 |
| 2015-05-14 | Perkins Adelene Q (President & CEO) | Sale | 10,000 | 12.18 | 121,800 |
| 2015-04-30 | Palombella Vito J. (Chief Scientific Officer) | Option Ex | 4,737 | 2.04 | 9,663 |
| 2015-03-16 | Perkins Adelene Q (President & CEO) | Sale | 20,000 | 16.00 | 320,000 |
| 2015-03-05 | Perkins Adelene Q (President & CEO) | Sale | 25,000 | 16.50 | 412,500 |
| 2015-01-29 | Perkins Adelene Q (President & CEO) | Sale | 20,000 | 14.83 | 296,540 |
| 2014-12-15 | Palombella Vito J. (Chief Scientific Officer) | Sale | 4,737 | 16.32 | 77,293 |
| 2014-12-15 | Palombella Vito J. (Chief Scientific Officer) | Option Ex | 4,737 | 2.04 | 9,663 |
| 2014-11-26 | Palombella Vito J. (Chief Scientific Officer) | Sale | 4,736 | 15.00 | 71,040 |
| 2014-11-26 | Palombella Vito J. (Chief Scientific Officer) | Option Ex | 4,736 | 2.04 | 9,661 |
| 2014-10-03 | Evnin Anthony B (Director) | Option Ex | 24,500 | 12.39 | 303,677 |
| 2014-09-30 | Evnin Anthony B (Director) | Sale | 112,451 | 13.56 | 1,525,285 |
| 2014-09-03 | Palombella Vito J. (Chief Scientific Officer) | Sale | 9,472 | 15.39 | 145,774 |
| 2014-09-03 | Palombella Vito J. (Chief Scientific Officer) | Option Ex | 9,472 | 2.04 | 19,322 |
| 2014-07-01 | Palombella Vito J. (Chief Scientific Officer) | Sale | 879 | 12.87 | 11,312 |
Insider trading activities including stock purchases, stock sales, and option exercises of INFI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Infinity Pharmaceuticals, Inc. (symbol INFI, CIK number 1113148) see the Securities and Exchange Commission (SEC) website.